Tag: Alterna LLC

Cedar Knolls, NJ July 10, 2012 – Alterna LLC, makers of Kerasal®, is progressing with its launch in Canada. The Canadian launch initiated in March of this year with the listing of two Kerasal SKUs at Shoppers Drug Mart and Pharmaprix stores. In recent months, Kerasal has added distribution in most Walmart stores, Jean Coutu, Uniprix, and other chains.
Kerasal is an iconic brand in foot care, with US distribution in all major chains and Walmart. Kerasal One Step Exfoliating Moisturizing Foot Ointment is the non-prescription brand most often recommended by U.S. podiatrists for softening severely dry feet. In addition to Kerasal One Step, Kerasal ultra20 Moisturizer Daytime Therapy Foot Softening Cream is available in Canada. Kerasal ultra20 is absorbed quickly by the skin, so it is perfect for daytime use.
“Canadian consumers, like our US customers, are savvy,” says Don Carswell, Director of International Sales at Alterna. “They want a product that is fast, effective and clinically proven. Kerasal One Step exfoliates and moisturizes the skin of the feet in a single step, which saves time and increases efficacy giving consumers softer feet faster.” Mr. Carswell noted that the Kerasal One Step Foot Ointment has been awarded the seal of approval by the Canadian Podiatric Medical Association.
Alterna is supporting the launch in Canada with national television advertising with English and French versions of its new television commercial. In addition to consumer support, Kerasal samples are being distributed to over 100 Canadian podiatrists who have requested samples. Alterna LLC, the US-based maker of Kerasal, has teamed up with Associated National Brokerage, Inc., of Newmarket, Ontario to serve its customers in Canada. Alterna plans to bring additional products to the Canadian market in the near future.

Cedar Knolls, NJ Jul 10, 2012 – Alterna LLC, makers of Kerasal® and Kerasal® Nail™, today announced that Kerasal Foot Ointment, already sold in approximately 3,200 Walmart stores, will be available in all 3,871 Walmart stores in late August. Kerasal Foot Ointment is the #1 one podiatrist recommended mass distributed non-prescription foot softener for severely dry feet, and has been sold in food, drug, and mass retail stores for over 8 years.
As a result of its successful launch this past year, Alterna’s newest product – Kerasal Nail Fungal Nail Renewal Treatment – will also expand its distribution at the world’s largest mass retailer from approximately, 1,300 stores to over 3,500 stores. Kerasal Nail is a clinically proven topical formula for rapidly improving the appearance of nails damaged by fungus or psoriasis. It is the only nail penetrating formula on the market with multiple clinical studies showing clinical signs of improvement in just two weeks. Alterna holds the exclusive license in the United States for the patented formula, developed by Moberg Derma AB.
Kerasal and Kerasal Nail are widely distributed, and also available at leading drug chains including Walgreens, CVS, and Rite Aid. Fueled by a multi-million dollar television and print advertising campaign, the Kerasal brand has experienced double digit retail sales growth over the last 52 weeks for 52 weeks ending May 13, 2012, according to data reported by IRI.

Whippany, NJ Aug 22, 2011 — Alterna LLC today announced the launch of Kerasal Nail – Fungal Nail Renewal Treatment, a new addition to the Kerasal® brand. Kerasal Nail is a topical formula that’s clinically proven to rapidly improve appearance of nails damaged or discolored by fungus and psoriasis. The product will be found on store shelves in the foot care aisle in major Walmart stores and Rite Aid stores this fall. Other major drug chains are expected to carry the product soon.
An estimated 30 million Americans suffer from unsightly and embarrassing nail appearance, a market currently underserved by nonprescription products. Kerasal Nail’s unique nail-penetrating formula has been licensed exclusively for the U.S. market from Moberg Derma AB, a leading Swedish pharmaceutical company. The product is already the #1 seller in various European countries where it launched last year.
Kerasal Nail’s patented formula combines the keratolyctic, nail softening, and hydrating effects of propylene glycol, urea and lactic acid to deeply penetrate the nail, and restore healthy appearance by normalizing thickened nails, reducing nail discoloration, and hydrating brittle nails. Kerasal Nail is odorless, preservative free and proven safe in clinical studies. In the most recent clinical study, over ninety percent of users saw improvement in nail appearance after 8 weeks, and more than three fourths saw improvement in appearance in just 2 weeks of use.
Kerasal Nail is easy to use, helping to ensure user compliance. It comes with a unique no-mess pinpoint silicone tip applicator, requires application just once a day, does not require filing of the nail, and dries quickly.
In a consumer research study of 500 fungal nail suffers, 77% said they would definitely or probably buy Kerasal Nail after seeing the concept. Alterna and Moberg are co-funding over $5 million worth of advertising and promotion to launch Kerasal Nail to the U.S. market, with heavy focus on television, print and consumer promotion. They expect to add at least $10 million of incremental retail sales to the category annually.

Whippany, NJ May 18, 2011 – Alterna LLC announced today that is has signed a new trademark and knowhow license agreement with Spirig Pharma AG of Egerkingen, Switzerland. This agreement expands Alterna’s exclusive rights to distribute Kerasal® One-Step Exfoliating Moisturizing Foot Ointment to 80 countries outside of North America. Alterna already owns the Kerasal® brand in North America, having fully acquired all rights to trademarks and product technology in 2006.
Spirig Pharma AG, Egerkingen is known internationally for brands like Daylong actinica®, a medical device for topical application for the prevention of certain forms of non-melanoma skin cancer in at risk patients, Daylong® liposomal sunscreen lotions and Excipial®, a range of skincare and moisturizer products.
Kerasal® foot ointment is clinically proven to soften severely rough, dry, cracked heels and feet by exfoliating and moisturizing skin in one easy step. Kerasal is approved by the American Podiatric Medical Association (APMA) and is the OTC brand recommended most by U.S. podiatrists. In the U.S., Kerasal is available for purchase in the foot care aisle in all major drug store chains and Walmart. According to IRI, retail sales of Kerasal in food, drug, and mass stores (excluding Walmart), were up 24.5% for the 52-week period ending March 20, 2011.
“We are very pleased to increase the depth of our international product portfolio,” says Steve Cagle, President and CEO of Alterna. “Spirig and Alterna have had a positive working relationship for a number of years, and we have been looking for additional avenues of cooperation that will generate win-win results.”
Alterna is making an aggressive push to expand distribution of its products in overseas markets. The significantly enlarged territory for Kerasal® offers a new opportunity, which should fuel the company’s continued sales growth. Since October, Alterna has signed distribution agreements with leading partners in Greece, Mexico, Honduras, Turkey and Trinidad & Tobago. The company’s distributors in Australia, Indonesia, Singapore and the Middle East have had record sales years, with most business coming from Alterna’s JointFlex® line of topical osteoarthritis pain products.
“We are seeing a strong interest in both Kerasal® and JointFlex® from outside the United States,” says Don Carswell, Director of International Sales at Alterna, “and we plan to serve these markets through top-tier partner companies that are based in-market, to promote and distribute our products.” “We highly welcome the expansion of our successful collaboration with Alterna LLC to a significant number of additional markets worldwide”, says Dr. Silvio Inderbitzin, CEO of Spirig Pharma AG